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Abstract: The treatment of bone a vascular necrosis is a big challenge considering the youthfulness of the patients in-
volved by necrosis in sickle cell disease and the importance of the generated disability. A vascular osteonecrosis is an 
epiphysis pathology which could be treated by joint replacement with success, however, multiple surgical procedures are 
mostly necessary during the patient’s life with a hazardous long term functional results. The treatment by autologous bone 
marrow grafting is an effective alternative which preserve the native joint. Using this mini-invasive high technology sur-
gical treatment in early stages, a joint replacement could be avoided in many patients. 
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1. INTRODUCTION 
  Sickle cell anemia, an autosomal-recessive disorder, is a 
hemolytic anemia characterized
 by abnormally shaped (sick-
led) red blood cells, which
 are removed from the circulation 
and destroyed at increased
 rates, leading to anemia [1-4]. Of 
greater clinical importance, the
 sickled RBCs cause vascular 
occlusion, which leads to tissue
  ischemia and infarction. 
Those who are homozygous for the sickle cell gene (hemo-
globin SS) have a high risk of bone osteonecrosis due to 
microvascular occlusion in relation with the disturbance in 
the erythrocyte architecture, the polymerization of hemoglo-
bin S (in a deoxygenated state) producing cells that are cres-
cent- or sickle-shaped with decreased deformability; the 
decreased deformability results in greater risk for clotting in 
small vessels. The incidence of osteonecrosis is also high in 
patients with hemoglobin SC (compound heterozygotes for 
HbS- and HbC-producing alleles: SC) and in the various 
types of sickle-beta-thalassemia (SThal) population. So, 
patients with sickle cell disease often present with orthopae-
dic disease manifestations requiring surgical intervention, 
with the most common indications being osteonecrosis and 
osteomyelitis [5-9]. Customarily, patients with osteonecrosis 
of the femoral head (ONFH) have been treated nonsurgi-
cally. However, purely medical treatment will allow only 
few patients to live with their condition for one or two years. 
Usually, the patients are kept off weight-bearing on the af-
fected side; however, this treatment principle has several 
limitations: the diseases frequently bilateral; it does not abol-
ish the muscle tone around the joint, even when the patient is  
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lying down. The use of two elbow crutches (as a substitute 
for axillary crutches) does not provide the required complete 
weight relief; and even if crutches afford some protection, 
there is still the question of how long the patients should be 
kept off weight-bearing. Between the diagnosis of ONFH 
and the loss of femoral head sphericity, up to 4 or 5 years 
may elapse. Strictly speaking, the patients should be kept off 
weight-bearing for this entire period of time. Seeing that the 
patients are usually young and in the midst of their working 
lives, it would be futile to attempt such prolonged weight 
relief. It should also be borne in mind that if patients are kept 
on non-surgical treatment for a long period of time, eventual 
surgery may come too late, since the lesions will, by then, 
have progressed to a stage where femoral head preserving 
surgery can no longer help. 
  Very early in the course of the disease, core decompres-
sion [10] remains the most logical treatment modality, if one 
accepts that the condition is a compartment syndrome, with 
increased pressure inside the femoral head. Core decompres-
sion has been in use for a considerable time; the results re-
ported by different authors vary no doubt because of differ-
ent patient populations and different ON stages treated with 
decompression. However, while fundamental research and 
clinical studies have shown that dead bone may be re-
vascularized by living bone, the reparative osteogenic poten-
tial is slight in ONFH: the number of bone progenitor cells in 
the uninvolved part of the femoral head and in the tro-
chanteric region is less than in healthy subjects. It would, 
therefore, make sense not only to core, but to introduce new 
cells. This can be done by placing a tibial graft, a vascular-
ized graft or cancellous bone into the coring tract. The same 
result may be produced more readily by harvesting bone 
marrow from the anterior iliac crests, concentrating the mar-
row thus obtained, and reinjecting it into the necrotic zones. Percutaneous Implantation of Autologous Bone Marrow Osteoprogenitor Cells  The Open Orthopaedics Journal, 2008, Volume 2    63 
  Once the femoral head has lost its sphericity, core de-
compression will still afford pain relief, but will not be able 
efficaciously and lastingly to halt the gradual collapse of the 
weight-bearing zone. The important goal to achieve at this 
stage is the immobilization of the necrotic segment. A mo-
bile segment will produce increased pressure in the femoral 
head, and may contribute to the progression of the necrosis. 
To this end, attempts have been made to use early recon-
struction, with debridement of the necrotic zone and re-
placement of the dead bone with autologous bone reinforced 
with a vascularized fibular graft, to support the subchondral 
bone at risk of collapse. This is an attractive approach, which 
does, however, require the patient to be kept off weight-
bearing for a long period of time (3 - 6 months). The surgery 
involved is technically demanding; the postoperative man-
agement is quite cumbersome (3 - 6 months off weight-
bearing); often, both hips are affected; and the treatment may 
not work. This is why only few patients have been managed 
in this way. 
  Since the survival of the cartilage cells is ensured by their 
nutrition from the synovial fluid, the femoral head may be 
restored to sphericity by elevating the necrotic segment and 
keeping it in this restored position, by the injection of ce-
ment. In this approach, acrylic cement is used to give the 
femoral head its correct shape, and to delay the progression 
to OA which follows the deformation of the head. Cement 
injection has several advantages: it allows immediate 
weight-bearing; it provides immediate pain relief; and it does 
not interfere with the patient’s work for an unduly long pe-
riod of time. Also, conversion to a hip replacement is 
straightforward, should the pain recur. In such cases, femoral 
head resurfacing would undoubtedly be a suitable treatment 
option. 
  For femoral head preserving surgery, osteotomies of 
various kinds (valgus, varus, flexion, deflexion, rotational) 
have been used for a long time. These osteotomies are still 
difficult to perform. Also, they may require prolonged 
weight relief after surgery, and conversion to hip replace-
ment in case of failure may be difficult. 
  The treatment by joint replacement is controversy be-
cause of the age of the patients involved and the number of 
complications observed in this disease. However, reconstruc-
tion and repair is usually incomplete after core decompres-
sion alone. One of the reasons of insufficient creeping substi-
tution to achieve bone remodeling after osteonecrosis may be 
the small number of progenitor cells present in the osteone-
crosis region in these patients [11]. In osteonecrotic hips, 
there is a decrease in osteogenic stem cells in the femoral 
head beneath the sequestrum and in the intertrochanteric 
region. This was confirmed by the extent of osteocyte death 
in the proximal femur seen in patients having total hip ar-
throplasty for osteonecrosis [12]. Avascular osteonecrosis 
treatment should therefore stimulate and influence bone 
remodeling by creeping substitution to preserve the integrity 
of the osteonecrotic zone. Using progenitor cells may be one 
means to achieving this. It seems sensible to not only use 
core decompression but also introduce new cells. This article 
includes a new approach to the conservative surgical man-
agement of patients with osteonecroses related to sickle cell 
disease. Autologous bone marrow transplantation was pro-
posed for the treatment of osteonecrosis in 1990 with good 
results [13-15]. We report in this study our technique and 
clinical results with this treatment in sickle cell disease. 
2. GRAFTING WITH AUTOLOGOUS BONE MAR-
ROW IN BONE AVASCULAR NECROSIS 
  In clinical practice, autologous bone marrow is harvested 
from the iliac crest and transplanted to the site of bone avas-
cular necrosis after concentration. 
2.1. Marrow Aspiration and Concentration 
  Bone marrow is aspirated under general anesthesia from 
the anterior or posterior iliac crest. After deep insertion of a 
beveled needle 8 cm long and 1.5 mm in diameter into can-
cellous bone, the marrow is aspirated into 10 ml syringe. 
300ml of marrow is aspirated in small fractions to reduce the 
degree of dilution by peripheral blood. Several perforations 
into the iliac crest, using the same skin incision, are some-
times necessary to obtain this marrow volume. The marrow 
is pooled in plastic bags containing cell culture medium and 
anticoagulant solution (citric acid, sodium citrate and dex-
trose). 
  The marrow is first filtered to separate cellular aggre-
gates and fat. It is then concentrated in a cell separator (Cobe 
2991, Gambro BCT, Paris, France). A 5 minutes centrifuga-
tion at 400 g force the polynuclear cell layer, which is heav-
ier because of its nuclei, to the periphery where it is collected 
and separated from the remainder of the marrow. The leuko-
cyte layer is removed at a flow rate of 100 ml per minute for 
45 seconds. The red cells are found in the centre and are 
recovered with the plasma. All that remained is the mononu-
clear layer containing the stem cells. This centrifugation 
technique reduces a 300 ml bone marrow aspirate to a 50 ml 
of stem cells. The procedure is about 40 minutes long, the 
patients’ remains under general anaesthesia during this time. 
2.2. Bone Marrow Grafting 
  The concentrated marrow is injected through a percuta-
neous approach using a 3-mm diameter trocar (trocar of 
Mazabraud, Collin, France) in the centre of the necrosis. 
This is performed through the major tuberosity for avascular 
necrosis of the humeral head, through the greater trochanter 
for avascular necrosis of the femoral head, through the lat-
eral or the medial condyle for avascular necrosis of the distal 
femur, or through an antero-medial approach for avascular 
necrosis of the proximal tibia. The position of the trocar is 
monitored with biplane fluoroscopy. 20 to 30 ml of concen-
trated bone marrow is injected through the trocar directly in 
the necrosis zone. During injection, the pressure increase, 
but a normal pressure pattern is restored once the injection is 
finished. There is no joint immobilization after the surgery. 
3. ASPIRATED AND REINJECTED MARROW 
CHARACTERISTICS 
  The number of nucleated cells obtained from bone mar-
row aspiration is estimated to be 16.4 millions cells per mL 
(± 11.5). In samples incubated in-vitro, the number of col-
ony-forming units is on average 12.4 ± 3.4 per 10
6 bone 
marrow nucleated cells. The differences between connective 
tissue progenitors harvested from various individual depend 
on many variables such as age, gender and local and sys-
temic disease. There is particularly a significant difference in 
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crest according to the etiologic factors of the osteonecrosis. 
The quantity of medullar nuclear cells per kg of marrow can 
be calculated using a formula that takes into account blood 
dilution. In each ml of aspirate, it was estimated that medul-
lar cells were represented by the difference between the 
nuclear cells count in the aspirate and that in peripheral 
blood, which is assessed during general anaesthesia. The 
number of nucleated cells of presumed medullar origin per 
kg is expressed as follows: 
N(10
8/kg) = (V  NP) - (V – 100)  NS/P 
where V, total volume of aspirate in ml, including the har-
vesting medium; NP, nuclear cell count per ml in the collec-
tion bag; V-100, the exact volume of aspirate, after subtrac-
tion of the 100 ml of harvesting medium; NS, the nuclear 
cell count per ml of peripheral blood drawn during the surgi-
cal procedure; and P, patient’s weight in kilograms. 
  Thus, for a total final volume of 400 ml (300 ml aspirate 
+ 100 ml medium) containing 16  10
6 nuclear cells per ml, 
obtained from a 70 kg adult with a leukocyte count of 4  
10
6 per ml, it may be estimated that the medullar nuclear cell 
count is 7  10
7 per kg. 
4. RESULTS 
  This technique was developed in the Henri Mondor Hos-
pital (Créteil, France) in 1990 and some patients have now a 
follow-up of 17 years. The clinical results of a prospective 
study of 189 symptomatic osteonecrotic hips in 116 patients 
treated with decompression and autologous bone marrow 
grafting were reported [15]. Among these patients, 38 had 
Sickle Cell Disease and these patients were followed up 
from 10 to 17 years. The mean age of the patients at the time 
of decompression and autologous bone marrow grafting was 
29 years (range, 16-41 years) and the number of hips was 56. 
The aim of this paper is to compare the evolution of these 
patients with the natural course of the disease as reported by 
the authors in an other study [18]. 
  The average total number of colony-forming units ob-
tained from bone marrow aspiration was estimated to be 37  
10
3 cells after culture of samples in vitro. After concentration 
(cell recovery: 84.3%) the average total number of colony-
forming units injected by hip was estimated to be 31  10
3 
cells. Patients were operated on before collapse (24 at Stage I 
and 32 at Stage II). Patients were followed up from 10 to 17 
years (mean 14 years). The outcome was determined by the 
changes in the Harris hip score [16], by progression in radio-
graphic stages according to Steinberg et al. classification 
[17], and by the need for hip replacement. No complication 
was recorded during the anaesthesia. Patients who did not 
require total hip arthroplasty (n =51) had a mean Harris hip 
score of 72 points preoperatively and 89 points postopera-
tively. Decompression and autologous bone marrow grafting 
decreased pain in all the patients postoperatively and delayed 
the progression of the disease to collapse during a period as 
long as 17 years for the patients with the longest follow-up 
and with an average period of 14 years for 87 % of the hips 
(49 among 56 hips) of this series. Total hip arthroplasty was 
necessary in 5 hips that progressed to collapse. 
  The mean preoperative volume of the osteonecrosis was 
26 cubic centimetres (minimum 12, maximum 30 cubic 
centimetres). The mean volume of the abnormal signal 
measured on MRI at the most recent follow-up (mean 10 
years) was 12 cubic. This means a reduction in percentage 
from 32% to 16% when the volume of the osteonecrosis is 
related to the volume of the femoral head. Fifteen hips dem-
onstrated total resolution of osteonecrosis on MRI. All had 
stage I osteonecrosis of the femoral head at the time of 
treatment with autologous bone marrow grafting. An abnor-
mal signal persisting as sequelae was on T1 images an in-
tralesional area of low intensity signal with a disappearance 
of the marginal band like pattern was present in the other 
hips operated at stage I. 
5. DISCUSSION 
  Our experience with autologous bone marrow grafting in 
sickle cell disease was begun as early as 1990. Our results 
demonstrate that autologous bone marrow grafting is an 
effective treatment for early stages related to sickle cell dis-
ease, that the technique is safe in this population of patients, 
and that bone repair in osteonecrosis was observed. 
  Decompression and autologous bone marrow grafting 
decreased pain in all the patients postoperatively and delayed 
the progression of the disease to collapse during a period as 
long as 17 years for the patients with the longest follow-up 
and with an average period of ten years for 87% of the hips 
(49 among 56 hips) of this series. In the natural history of the 
disease stage progression occurred regardless of stage at the 
initial visit: among the patients of the historical series [18], 
thirty-two hips were seen with stage I at the initial visit, and 
forty-three hips were observed at stage II at the initial visit 
and among the seventy-five hips, sixty-five hips (87 percent) 
demonstrated collapse within five years after the diagnosis. 
In the actual series (with treatment by bone marrow graft-
ing), only seven (12.5 per cent) among fifty-six hips demon-
strated collapse at a follow-up of five years. The Kaplan-
Meier curves, showed significant longer durations of sur-
vival before collapse for the 56 hips with autologous bone 
marrow grafting than for the 75 hips of the historical series 
without treatment (p < 0.01). 
  The effectiveness of bone-marrow mononuclear cells 
may be related to the availability of stem cells endowed with 
osteogenic properties arising from an increase in the supply 
of such cells to the osteonecrotic zone through bone-marrow 
implantation [19-22]. Another explanation for the therapeu-
tic effect of bone-marrow implantation is that injected mar-
row stromal cells secrete angiogenic cytokines, resulting in 
increased angiogenesis and subsequent improvement in os-
teogenesis. 
  In concluding patients with osteonecrosis related to SCD 
can be severely disabled by the status of their hip. Total hip 
arthroplasty (THA) remains for some of these patients the 
only surgical option according to the status of their hip when 
severe degenerative changes are present after collapse. How-
ever, because the results of reports of THA in SCD involve a 
higher complications rate and incidence of failure with revi-
sion than arthroplasty in osteonecrosis [23, 24] related to 
other conditions, it is important to know that other surgical 
options exist for early stages of this disease: core decom-
pression and physical therapy, bone marrow transplantations, 
and cementoplasty. These treatments should be recom-
mended at early stages of osteonecrosis to postpone the need 
for hip arthroplasty. Percutaneous Implantation of Autologous Bone Marrow Osteoprogenitor Cells  The Open Orthopaedics Journal, 2008, Volume 2    65 
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Fig. (1). Comparison of the natural evolution of hip osteonecrosis with the evolution after percutaneous implantation of bone marrow. 